Tavneos (avacopan) approved for ANCA associated vasculitis in Japan

It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan

HUTCHMED initiates a Japan bridging study to Support Surufatinib

Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan

Japan to purchase 150 million doses of Novavax’ Covid-19 vaccine from Takeda

Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022

Japan approves AstraZeneca’s Forxiga for chronic kidney disease

Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025

BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan

The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions

Sumitomo Pharma bags world-first go-ahead for iPS cell therapy to treat Parkinson’s disease

The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%

KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients

Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention

Asahi Kasei Pharma & Alchemedicine launch first human trials for hard-to-treat diseases drugs